

1 **Running Title:** Sentinel Surveillance for SARS-CoV-2 in Malawi (*46 characters*)

2 **Keywords:** COVID-19, Malawi, Sentinel surveillance

3 **Title:** Monitoring COVID-19 Occurrence in a Resource-limited Setting – COVID-19 Sentinel
4 Surveillance in Malawi

5 **Authors:** Godwin Ulaya¹, Alinune Kabaghe², Christel Saussier¹, Ellen MacLachlan³, Joshua
6 Smith-Sreen⁴, Chaplain Katumbi¹, George Bello¹, Terence Tafatatha², Limbikani Chaponda⁵,
7 Bernard Mvula⁵, Matthews Kagoli⁵, Benson Chilima⁵, Joseph Bitilinyu- Bangoh⁵, Laphiod
8 Chisuwo⁵, Yusuf Babaye¹, Moses Chitenje¹, Barbara Bighignoli¹, Fred Bangara², Ireen
9 Namakhoma¹, Annie Chauma-Mwale⁵, Gabrielle O’Malley³, Kelsey Mirkovic⁶ Nellie Wadonda-
10 Kabondo²

11 **Affiliations:**

12 ¹International Training and Education Center for Health (I-TECH) Malawi, University of
13 Washington, Lilongwe, Malawi (G. Ulaya, C. Saussier, C. Katumbi, G. Bello, Y. Babaye, M.
14 Chitenje, B. Bighignoli, I. Namakhoma); ²Division of HIV and TB, US Centers for Disease
15 Control and Prevention Lilongwe, Malawi (A.N. Kabaghe, T. Tafatatha, F. Bangara, Nellie
16 Wadonda- Kabondo); ³International Training and Education Center for Health (I-TECH),
17 University of Washington, Seattle, Washington, USA (E.W. MacLachlan, G. O’Malley); ⁴Alpert
18 Medical School of Brown University, Providence, USA (J. Smith-Sreen); ⁵Public Health Institute
19 of Malawi (PHIM), Lilongwe, Malawi (L. Chaponda, B. Mvula, M. Kagoli, B. Chilima, J.
20 Bitilinyu- Bangoh, L. Chisuwo, A. Chauma-Mwale); ⁶Amgen Biotechnology Research (K.
21 Mirkovic).

22 Abstract

23 The routine COVID-19 surveillance in Malawi that relied on retrospective reporting could not
24 efficiently steer timely measures to the rapidly evolving pandemic. To monitor real-time changes
25 in infections and inform the COVID-19 response, we implemented an active sentinel
26 surveillance system from July to December 2022. SARS-CoV-2 symptomatic and asymptomatic
27 patients in selected health facilities (HFs) and anyone aged ≥ 5 years entering at Point of Entry
28 (PoEs) sites were eligible to participate. Self-reported epidemiological and clinical data, and
29 nasopharyngeal specimens were collected from 9,305 participants. A higher overall SARS-CoV-
30 2 RT-PCR positivity rate was observed at HFs, 8.9% among symptomatic and 6.5% among
31 asymptomatic patients, versus 3.5% at PoEs. The positivity trends among symptomatic and
32 asymptomatic patient groups showed a similar pattern throughout the period. This active
33 surveillance complemented routine surveillance, especially during a low incidence period and
34 highlighted the need to target both symptomatic and asymptomatic population.

35 Introduction

36 SARS-CoV-2 infection was first confirmed in Malawi on 2nd April 2020 (1). The Government
37 of Malawi subsequently activated a national Public Health Emergency Operations Center to
38 coordinate the multisectoral response to the COVID-19 pandemic (2). Despite the government's
39 initial response within the capacity of its resources, the surge of cases in the communities and the
40 porous Points of Entry (PoEs) posed challenges to track changes in the incidence of COVID-19.
41 Additionally, the limited investment in and prioritization of public health programs contributed
42 to inadequate capacity in some health facilities (HFs) to routinely test for SARS-CoV-2. As a
43 result, there was a reduced ability to detect cases and monitor changes in real-time (3). Although

44 suspected COVID-19 cases were confirmed using both rapid diagnostic and polymerase chain
45 reaction (PCR) testing and reported, surveillance was passive and circulating variants were not
46 systematically tracked. The testing algorithm used in Malawi was restricted to those that were
47 symptomatic, despite evidence of transmissibility of laboratory-confirmed SARS-CoV-2
48 infections among asymptomatic individuals (4).

49 Although preventive and mitigation measures were recommended, periods of low reported
50 COVID-19 incidence were accompanied with a noticeable general decline in adherence to these
51 measures within communities and among healthcare workers. There was also relaxation in the
52 overall routine surveillance system, with reduced testing and delayed reporting. Moreover, the
53 emergence of the polio and cholera outbreaks in early 2022 compounded the situation and
54 diverted attention and resources away from passive COVID-19 surveillance, further hindering
55 the monitoring of the COVID-19 situation in Malawi (5,6). In response to these challenges, the
56 Public Health Institute of Malawi (PHIM) established an active, real-time COVID-19 sentinel
57 surveillance. This system was designed to complement routine surveillance by rapidly detecting
58 changes in COVID-19 cases and allowing better characterization of COVID-19 and associated
59 risk factors (7). The surveillance system objectives were to detect an increase in SARS-CoV-2
60 infections early, to characterize persons and locales at greater risk, and to identify possible
61 reasons for increased risk. In this paper, we describe the trends in SARS-CoV-2 symptomatic
62 and asymptomatic cases and their demographic and behavioral characteristics during the first six
63 months of the COVID-19 sentinel surveillance in Malawi.

64 Methods

65 Sentinel surveillance design

66 This was a surveillance initiative that aimed at monitoring epidemiological and clinical trends in
67 SARS-CoV-2 infection among sampled persons at sentinel sites in Malawi. The COVID-19
68 sentinel surveillance methodology was adapted from the WHO recommendations on integrated
69 sentinel surveillance of influenza and SARS-CoV-2. (7)

70 Sentinel surveillance locations

71 The sentinel surveillance was set up in July 2022 in seven purposively selected sites in seven
72 districts: five HFs— Limbe Health Centre (Blantyre), Bwaila Hospital (Lilongwe), Matawale
73 Health Centre (Zomba), Mzuzu Urban Health Centre (Mzimba North), and Mangochi District
74 Hospital (Mangochi)— and two border PoEs—Mwanza border (Mwanza) and Songwe border
75 (Karonga) (**Figure 1**). The HFs were selected from the districts with the highest number of
76 reported SARS-CoV-2 infections and from facilities with a high volume of patients (8). The
77 PoEs were selected due to their high-volume of incoming travelers from Mozambique and
78 Tanzania, respectively.

79 **Figure 1: Map showing the seven COVID-19 sentinel sites across Malawi, July – December**

80 **2022** *HF: health facility, POE: point of entry*

81 Study Populations

82 In HFs, the study population consisted of patients of any age seeking healthcare for any reason.
83 We excluded severely ill patients, those under 18 years old without a legal guardian, or those

84 who had previously participated in the survey within 14 days. Eligible participants were screened
85 through clinical assessment and categorized into SARS-CoV-2 symptomatic or asymptomatic
86 based on the WHO integrated COVID-19 and Influenza case definition. The symptomatic
87 patients had symptoms of COVID-19/Influenza while asymptomatic group did not fulfil the case
88 definitions¹ (7). At the borders, persons ≥ 5 years of age entering the country were eligible to
89 participate. In both populations, eligible participants or their guardians had to provide consent.

90 Sample Size and Sampling strategy

91 The HF sample size calculation assumed a SARS-CoV-2 infection prevalence of approximately
92 2% within the general HF population based on unpublished results from previous local COVID-
93 19 surveys. To ensure detection of at least one case of SARS-CoV-2 infection per week, given
94 the 2% assumed prevalence and an estimated 10% refusal rate, each site aimed to recruit 50
95 symptomatic and 25 asymptomatic participants per week. This approach was consistent with
96 WHO guidance on integrated SARS-CoV-2/Influenza surveillance (7).
97 Similarly, the sample size for the PoEs followed the same assumptions—a 2% infection
98 prevalence and a 10% refusal rate— aiming to detect at least one SARS-CoV-2 case per week.
99 Based on WHO technical guidance for SARS-CoV-2 surveillance, each PoE had an enrollment
100 target of 50 travelers per week.
101 As part of sampling procedures, all participants in HFs were screened while entering the facility
102 gate using an eligibility checklist and categorized as asymptomatic and symptomatic. From
103 Mondays to Fridays, the first ten symptomatic and the first five asymptomatic eligible patients
104 were then selected to participate through consecutive sampling.

105 For PoE, each week, a sampling interval was determined based on the estimated number of
106 travelers crossing the border until a maximum of 50 participants were enrolled each week. A
107 total of 10 travelers daily were selected from points of entry using systematic sampling,
108 regardless of the presence of COVID-19 symptoms.

109 Data and specimen collection

110 Before rolling out the implementation of the COVID-19 sentinel surveillance, all staff were
111 trained on the protocol procedures. A dedicated surveillance assistant oversaw activities at each
112 site and was responsible for data entry and quality control. Questions were administered using a
113 structured questionnaire installed on an electronic tablet using the Open Data Kit (ODK)
114 platform. The questionnaire was available in English, Chichewa, Tumbuka and KiSwahili. We
115 collected self-reported information on socio-demographics, past exposure to COVID-19, current
116 signs and symptoms of influenza-like illness, contact with PCR-confirmed SARS-CoV-2–
117 infected persons, national and international travel, attendance to gatherings, adherence to
118 COVID-19 preventive measures, underlying health conditions— HIV, cardiovascular disease,
119 chronic respiratory disease, diabetes, and other medical conditions—, and vaccination against
120 COVID-19.

121 A nasopharyngeal (NP) specimen was collected from all participants. The NP specimens were
122 immediately put in viral transport media and transported in temperature regulated cooler boxes
123 for storage at 2-8 °C before testing. NP specimen tests were done at the sentinel facilities
124 utilizing RT-PCR GeneXpert platforms within 24 hours of collection. Specimens that tested
125 positive for SARS-CoV-2 were stored in minus 80 degrees freezers within 72 hours of specimen
126 collection prior to shipment to the PHIM national reference laboratory for genomic sequencing.
127 All test results were incorporated into the routine surveillance system. The district health offices

128 where the cases were detected were responsible for communicating the test results to the
129 participants.

130 **Data management and analysis**

131 Data collected was daily sent through internet connection to a secure server. The data were
132 downloaded from the server and imported into Stata software, version 14.2 for data cleaning and
133 analysis (9). Each participant was assigned a unique identifier upon enrollment for linking ODK
134 data and laboratory results. If values exceeded clinically expected ranges, queries were sent to
135 the concerned site to confirm their validity. Data from all the sentinel sites were assessed for
136 consistency on a weekly basis. Outputs tables and graphs including weekly and cumulative
137 enrolment figures, collected specimens, PCR results, and vaccination status for all participants
138 were generated on a weekly basis and shared with the PHIM for investigation and action.
139 COVID-19 vaccination status was self-reported by participants. Participants who reported two
140 doses of COVID-19 AstraZeneca or Pfizer vaccine or one dose of COVID-19 Johnson &
141 Johnson vaccine were categorized as “fully vaccinated” while those receiving one dose of
142 COVID-19 AstraZeneca or Pfizer vaccine were categorized as “partially vaccinated”. Those
143 without any dose of any vaccine were categorized as “not vaccinated at all”.
144 We conducted descriptive [frequencies, medians, and interquartile ranges (IQRs)] and bivariate
145 analyses (not included in this manuscript) of sociodemographic and clinical factors and
146 associations with RT-PCR positivity rates (PR). We also compared PRs between symptomatic
147 participants, asymptomatic participants, and travelers. Multivariable analyses assessed
148 associations between PRs and various sociodemographic and clinical factors, adjusting for
149 potential confounders: sex, age, education, time since last positive SARS-CoV-2 test, and contact
150 with a positive SARS-CoV-2 case. Independent variables were occupation, travelling outside the

151 country, COVID-19 vaccination status, time since last vaccination, underlying factors and
152 pregnancy. We applied multivariable logistic regression (binary outcome was a positive or
153 negative PCR result) incorporating covariates selected based on epidemiological and statistical
154 importance from bivariate analyses (chi-square). Crude and adjusted odds ratios (aOR) and 95%
155 confidence intervals (CIs) were calculated. We considered a P value ≤ 0.05 to be statistically
156 significant.

157 Ethical considerations

158 Ethics approvals were granted by the National Health Services Research Council (Reference
159 NHSRC # 22/04/2896) and the protocol was reviewed by CDC, deemed not research, and was
160 conducted consistent with applicable federal law and CDC policy (10,11).

161 All participants gave their written informed consent or assent prior to their participation in the
162 surveillance procedures. Informed consent from a guardian was required for all children under 18
163 years of age, except for emancipated minors.

164 Results

165 Participant Screening and Enrollment

166 A total of 9,981 individuals were screened across all seven sentinel sites. Among them, 4.7%
167 (n=471) were excluded from the study, either because they refused to give consent/assent
168 (n=102) or were ineligible based on surveillance exclusion criteria (n=369). A total of 9,510
169 participants (95.3%) were enrolled; 205 declined to provide NP specimens and were excluded. A
170 total of 9,305 participants (93.2%) provided both the NP specimens and responded to the
171 questionnaire (**Figure 2**).

172 **Figure 2: Flow diagram of participants inclusion, COVID-19 sentinel surveillance, Malawi,**
173 **July -December 2022**

174 **Participant Characteristics by Sentinel Surveillance Site Type and**
175 **Symptom Status**

176 **Error! Reference source not found.** provides a summary of participant characteristics
177 categorized by type of sentinel surveillance site and symptom status. In HFs, fewer participants
178 were enrolled at Mzuzu and Limbe health centers (15.6% and 15.0% respectively). More
179 participants were enrolled at Mwanza PoE (59.5%) compared to Songwe PoE (40.5%). Most of
180 the respondents enrolled at the health facilities were aged between 15 to 29 years (45.9% among
181 symptomatic and 43.9% among asymptomatic) and most enrolled travelers were aged 30-49
182 years (59.0%). At HFs, females represented 61.1% and 61.9% of asymptomatic and symptomatic
183 groups, respectively. Among travelers, 70.7% were males. Most of the respondents had attended
184 secondary education in both the HFs (72.7%) and PoEs (76.0%).

185 In the HFs, most of the respondents in both symptomatic and asymptomatic groups were
186 “unemployed” (39.3% and 46.7% respectively). At PoEs, most participants were either
187 employed or in business (46.5%).

188 About three quarters of the respondents in each category were not vaccinated: 74.4% of
189 symptomatic patients, 77.0% of asymptomatic patients and 70.3% of travelers. Less than one
190 fifth in each category were fully vaccinated: 19.4% symptomatic, 19.9% asymptomatic and
191 18.1% of travelers.

192 Most respondents reported no underlying health condition (83.6%). Among the self-reported
 193 underlying conditions, HIV was the most reported: 5.3% of symptomatic patients, 10.8% of
 194 asymptomatic and 4.7% of travelers.

195 **Table 1: Characteristics of enrolled participants by symptom status and type of sentinel**
 196 **surveillance site), COVID-19 sentinel surveillance, Malawi, July-December 2022**

		Patients at health facilities		Travelers at	Total study
		Symptomatic	Asymptomatic	points of	population
		N=4880	N= 2690	entry (POEs)	N=9305
		n (%)	n (%)	n (%)	n (%)
Characteristic					
Sentinel Site					
Health Facilities	Mzuzu Urban	1033 (21.2)	150 (5.6)	NA	1183 (15.6)
	Bwaila	1096 (22.5)	655 (24.3)	NA	1751 (23.1)
	Mangochi	1099 (22.5)	740 (27.5)	NA	1839 (24.3)
	Matawale	993 (20.3)	670 (24.9)	NA	1663 (22.0)
	Limbe	659 (13.5)	475 (17.7)	NA	1134(15.0)
POEs	Songwe	NA	NA	703 (40.5)	703 (40.5)
	Mwanza	NA	NA	1032 (59.5)	1032 (59.5)
Age (years)	0-14	236 (4.8)	102 (3.8)	41 (2.4)	379 (4.1)
	15-29	2240 (45.9)	1183 (43.9)	514 (29.6)	3937 (42.3)
	30-49	1858 (38.1)	1104 (41.0)	1024 (59.0)	3986 (42.8)
	≥50	546 (11.2)	301 (11.2)	156 (9.0)	1003 (10.8)
Median, years (IQR)		29 (17)	30 (16)	34 (13)	31 (17)
Sex	Female	2981 (61.1)	1664 (61.9)	509 (29.3)	5154 (55.4)
	Male	1899 (38.9)	1026 (38.1)	1226 (70.7)	4151 (44.6)
Highest level of education	None	316 (6.5)	117 (4.4)	11(0.6)	444 (4.8)
	Primary	1089 (22.3)	541 (20.1)	405 (23.3)	2035 (21.9)
	Secondary	3475 (71.2)	2032 (75.5)	1319 (76.0)	6826 (73.3)
Occupation	In school	706 (14.5)	282 (10.5)	137 (7.9)	1125 (12.1)
	Employed/Business	1568 (32.1)	793 (29.5)	806 (46.5)	3167 (34.0)
	Farmer	690 (14.1)	358 (13.3)	89 (5.1)	1137 (12.2)
	Unemployed	1916 (39.3)	1257 (46.7)	703 (40.5)	3876 (41.7)

Vaccination Status	Non-Vaccinated	3631 (74.4)	2070 (77.0)	1220 (70.3)	6921 (74.4)
	Partially vaccinated	303 (6.2)	192 (7.1)	199 (11.5)	694 (7.5)
	Full vaccination	946 (19.4)	428 (19.9)	316 (18.2)	1690 (18.1)
Underlying Conditions	HIV	259 (5.3)	290 (10.8)	81 (4.7)	630 (6.8)
	CV diseases*	180 (3.7)	66 (2.5)	42 (2.4)	288 (3.1)
	Chronic respiratory disease [†]	204 (4.2)	35 (1.3)	21 (1.2)	260 (2.8)
	Diabetes	30 (0.6)	18 (0.7)	10 (0.6)	58 (0.6)
	Others	127 (2.6)	80 (3.0)	33 (1.9)	240 (2.6)
	None	4080 (83.6)	2201 (81.8)	1548 (89.2)	7829 (84.1)

197 *CV diseases: chronic cardiac disease and hypertension.

198 [†]Chronic respiratory disease: including asthma and tuberculosis.

199 COVID-19 Positivity Rate Trends among Health Facility Respondents and 200 Travelers

201 **Figure 3** shows trends of COVID-19 positivity rate in those recruited at the HFs and the
202 travelers. The highest overall positivity rate of 29.6% was recorded in the week of 11-15 July
203 2022 when the lowest number of participants were recruited (n=136) while the lowest positivity
204 of 0.9% was recorded in the week of 24-28 October 2022 (n=334). The average overall positivity
205 rate was 8.0%. The highest number of participants recruited was 531 in the week of 12-16
206 December 2022. On average 372 participants were recruited every week. Throughout the sentinel
207 surveillance period, the positivity trends among the symptomatic and asymptomatic patients
208 showed a similar pattern, with the symptomatic group showing slightly higher rates in most of
209 the time points.

210 **Figure 3: Trends of cumulative COVID-19 positivity rate, overall, among symptomatic and**
211 **asymptomatic, and travelers, COVID-19 sentinel surveillance, Malawi, July-December**
212 **2022.**

213

214 Association of COVID-19 Positivity with Demographics and Behavioral

215 Factors

216 **Table 2** presents the association of SARS-CoV-2 positivity rate with various demographic and
217 behavioral factors categorized by symptomatic patients, asymptomatic patients, and travelers.

218 The results of unadjusted results are only presented in the table. Below is a description of
219 adjusted model results.

220 Symptomatic patients

221 After adjusting for all potential confounders, those who were partially vaccinated remained more
222 likely to test positive compared to those who were not vaccinated (aOR: 1.7; 95% CI: 1.2-2.5).

223 Participants that enrolled at Mzuzu Urban and Mangochi health facilities were more likely to test
224 positive to SARS-CoV-2 than those at the referenced facility (Mzuzu Urban: aOR:3.9; 95%

225 CI:2.7-5.4; Mangochi: aOR: 1.6 95% CI: 1.1-2.3).

226 Asymptomatic patients

227 In adjusted model, those who had travelled outside Malawi within the previous 14 days were less
228 likely to test positive for SARS-CoV-2 compared to those that had not travelled (aOR: 0.4; 95%

229 CI: 0.1-0.9). Those who enrolled at Mzuzu Urban health facility were more likely to test positive
230 to SARS-CoV-2 than those at the referenced facility (aOR: 3.2; 95% CI: 1.7-5.9).

231 Travelers

232 In adjusted model, students remained more likely to test positive for SARS-CoV-2 compared to
233 those unemployed or retired (aOR: 2.9; 95% CI: 1.1-7.9). Travelers who were fully vaccinated

234 were more likely to test positive for SARS-CoV-2 compared to those that were not vaccinated
235 (aOR: 2.5; 95% CI: 1.4-4.5).

236 **Table 2: Association of SARS-CoV-2 positivity rates with demographic and behavioral factors, COVID-19 sentinel**
 237 **surveillance, Malawi, July-December 2022**

	Health facilities						Travellers at POEs		
	Symptomatic patients n=4880			Asymptomatic patients n=2690			N=1735		
	Percent positivity (95% CI)	Unadjusted OR (95% CI)	Adjusted* OR (95% CI)	Percent positivity (95% CI)	Unadjusted OR (95% CI)	Adjusted* OR (95% CI)	Percent positivity (95% CI)	Unadjusted OR (95% CI)	Adjusted* OR (95% CI)
Overall SARS-CoV-2 positivity rate (%)	8.9 (8.1-9.7)	NA	NA	6.5 (5.6-7.5)	NA	NA	3.5 (2.6-4.4)	NA	NA
Sex									
Male	8.2 (6.9-9.4)	Reference		7.2 (5.7-8.9)	Reference		3.3 (2.3-4.4)	Reference	
Female	9.3 (8.3-10.4)	1.2 (0.9-1.4)		6.1 (4.9-7.3)	0.8 (0.6-1.1)		3.9 (2.4-6.0)	1.2 (0.7-2.1)	
Age in years									
0-14‡	8.8 (5.5-13.2)	Reference		6.9 (2.8-13.6)	Reference		4.9 (0.5-16.5)	Reference	
15-24	9.1 (7.9-10.3)	1.0 (0.6-1.6)		6.0 (4.7-7.5)	0.9 (0.4-1.9)		3.7 (2.2-5.7)	0.9 (0.6-1.4)	
25-49	8.3 (7.1-9.6)	0.9 (0.6-1.5)		6.8 (5.4-8.4)	0.9 (0.4-2.2)		3.6 (2.5-4.9)	0.8 (0.6-1.2)	
50+	9.7 (7.3-12.5)	1.1 (0.6-1.9)		7.3 (4.6-10.8)	1.1 (0.4- 2.5)		1.3 (0.2-4.5)	0.9 (0.6-1.5)	
Education									
None	13.9 (10.3-18.2)	Reference		4.3 (1.4-9.6)	Reference		0	Reference	
Primary	9.6 (2.0-25.7)	0.7 (0.2-2.3)		15.4 (1.9-45.4)	4.1 (0.7-23.5)		8.3 (0.2-38.5)	NA	
Secondary	8.5 (7.7-9.3)	0.6 (0.4-0.8)		6.6 (5.6-7.6)	1.6 (0.6-3.9)		3.5 (2.7-4.5)	NA	
Occupation									
Unemployed/ Retired	6.9 (5.8-8.1)	Reference	Reference	5.9 (4.7-7.3)	Reference	Reference	3.6 (2.3-5.2)	Reference	Reference
Student	10.5 (8.3-12.9)	1.5 (1.2-2.1)	1.2 (0.8-1.7)	7.4 (4.7-11.1)	1.3 (0.7-2.1)	0.8 (0.4-1.4)	8.0 (4.1-13.9)	2.4 (1.1-4.9)	2.9 (1.1-7.9)
Employed/ Business	10.8 (9.3-12.4)	1.6 (1.3-2.1)	1.3 (1.0-1.7)	8.3 (6.5-10.5)	1.5 (1.0-2.0)	1.0 (0.7-1.6)	2.6 (1.6-3.9)	0.7 (0.4-1.3)	0.6 (0.2-1.4)
Farmer	8.5 (6.4-10.7)	1.2 (0.9-1.7)	1.4 (1.0-1.9)	3.9(2.2-6.5)	0.7 (0.4-1.2)	0.6 (0.3-1.1)	3.4 (0.7-9.5)	0.9 (0.3-3.2)	0.8 (0.2-2.9)
Time since last positive SARS-CoV-2 test									
Within last	33.3 (7.4-70.0)	Reference		14.3 (3.0-36.3)	Reference		0	Reference	

month									
Within 2 to 3 months ago	0 (0-15.4)	NA		14.3 (0.1-57.8)	2.5 (0.1-46.7)		0	NA	
More than 3 months ago	6.7 (3.7-11.1)	0.7 (0.2-2.4)		4.9 (1.9-9.8)	0.8 (0.1-6.7)		0	NA	
Contact with confirmed case in past 14 days									
No	8.7 (7.9-9.5)	Reference		6.4 (5.5-7.4)	Reference		3.4 (2.6-4.4)	Reference	
Yes	13.3 (8.1-19.9)	1.6 (0.9- 2.6)		8.8 (3.3-18.2)	1.4 (0.6-3.3)		5.0 (0.1-24.8)	1.5 (0.2-11.2)	
Travelled outside the country in past 14 days									
No	8.9 (8.1-9.7)	Reference	Reference	6.7 (5.7-7.7)	Reference	Reference	3.3 (1.7-5.7)	Reference	Reference
Yes	0	NA	NA	2.9 (0.9-6.7)	0.4 (0.2-1.0)	0.4 (0.1-0.9)	3.5 (2.5-4.6)	1.1 (0.6-2.0)	0.9 (0.4-1.8)
Vaccination status†									
Unvaccinated	7.9 (7.0-8.8)	Reference	Reference	6.3 (5.2-7.4)	Reference	Reference	3.1 (0.1-3.5)	Reference	Reference
Partially vaccinated	13.2 (9.6-17.5)	1.8 (1.2-2.5)	1.7 (1.2-2.5)	5.7 (2.8-10.0)	0.9 (0.5-1.7)	0.8 (0.4-1.4)	1.0 (3.9-9.6)	0.3 (0.1-1.3)	0.4 (0.1-1.6)
Fully vaccinated	11.1 (9.1-13.2)	1.4 (1.1-1.8)	1.1 (0.9-1.4)	7.9 (5.5-10.9)	1.3 (0.9-1.9)	1.1 (0.7-1.7)	6.3 (2.2-4.2)	2.1 (1.2-3.7)	2.5 (1.4-4.5)
Time since last vaccination									
< 6 months	9.1 (3.0-19.9)	Reference	Reference	14.34.0-32.6)	Reference	Reference	0	Reference	Reference
>= 6 months	8.9 (8.0-9.7)	0.9 (0.4-2.5)	1.0 (0.4-2.7)	6.4 (5.5-7.4)	0.4 (0.1-1.2)	0.4 (0.1-1.3)	3.5 (2.6-4.4)	NA	NA
	Preexisting medical condition								
Any underlying medical condition									
No	8.4 (7.6-9.3)	Reference	Reference	6.3 (5.3-7.3)	Reference	Reference	3.5 (2.6-4.5)	Reference	Reference
Yes	11.3 (9.0-13.7)	1.4 (1.1-1.7)	1.6 (1.0-2.6)	7.4 (5.2-10.1)	1.2 (0.8-1.7)	2.1 (1.0-4.2)	2.8 (0.9-6.3)	0.8 (0.3-1.9)	0.2 (0.1-2.7)
Diabetes mellitus									
No	8.9 (8.0-9.7)	Reference	Reference	6.5 (5.6-7.5)	Reference	Reference	3.5 (2.6-4.4)	Reference	Reference
Yes	10.0 (2.1-26.5)	1.1 (0.3-3.8)	0.8 (0.2-2.8)	0	NA	NA	0	NA	NA
Chronic heart disease including hypertension									
No	8.7(7.9-9.5)	Reference	Reference	6.5 (5.5-7.4)	Reference	Reference	3.4 (2.6-4.4)	Reference	Reference
Yes	13.3 (8.7-19.1)	1.6 (1.0-2.5)	0.9 (0.5-1.6)	7.6 (2.5-16.8)	1.2 (0.5-2.9)	0.5 (0.2-1.6)	5.9 (0.5-16.1)	1.4 (0.3-5.9)	4.6 (0.4-54.7)

Weakened immune system**										
No	8.9 (8.1-9.7)	Reference	Reference	3.5 (5.5-7.5)	Reference	Reference	7.2 (2.6-4.5)	Reference	Reference	
Yes	8.1 (5.0-12.1)	0.9 (0.6-1.4)	0.6 (0.3-1.0)	2.5 (4.2-10.4)	1.1 (0.7-1.7)	0.5 (0.2-1.1)	6.8 (0.3-8.6)	0.9 (0.7-1.3)	2.0 (0.1-29.9)	
Asthma										
No	8.9 (8.0-9.7)	Reference	Reference	6.5 (5.6-7.5)	Reference	Reference	3.4 (2.6-4.3)	Reference	Reference	
Yes	8.5 (4.1-15.1)	0.9 (0.5-1.8)	0.6 (0.3-1.3)	3.6 (0.9-18.3)	0.5 (0.1-3.9)	0.3 (0.1-2.4)	7.7 (0.1-36.0)	2.3 (0.3-18.4)	7.5 (0.4-128.2)	
Chronic respiratory disease										
No	8.8 (8.0-9.6)	Reference	Reference	6.5 (5.6-7.5)	Reference	Reference	3.5 (2.6-4.4)	Reference	Reference	
Yes	15.8 (7.4-27.8)	1.9 (0.9-3.9)	1.2 (0.5-2.9)	0	NA	NA	0	NA	NA	
Pregnant										
No	8.9(8.1-9.7)	Reference	Reference	6.5 (5.6-7.5)	Reference	Reference	3.4 (2.6-4.3)	Reference	Reference	
Yes	5.5(1.1-15.1)	0.6 (0.2-1.8)	0.7 (0.2-2.3)	5.6 (0.1-27.2)	0.8 (0.1-6.3)	0.8 (0.1-6.1)	14.3 (0.3-57.8)	4.7 (0.6-39.7)	8.3 (0.9-77.6)	
Health Facility										
Bwaila	83.(7.0-9.4)	Reference	Reference	8.0 (6.2-10.2)	Reference	Reference	NA	NA	NA	
Mzuzu Urban	19.5 (16.8-20.9)	4.1 (3.0-5.5)	3.9 (2.7-5.4)	13.9 (9.3-19.7)	3.2 (1.8-5.5)	3.2 (1.7-5.9)	NA	NA	NA	
Mangochi	7.7 (5.9-8.2)	1.6 (1.1-2.2)	1.6 (1.1-2.3)	6.2 (4.7-7.9)	1.2 (0.8 – 1.9)	1.4 (0.9-2.3)	NA	NA	NA	
Matawale	4.1 (3.2-4.9)	0.8 (0.5-1.2)	0.8 (0.5-1.2)	3.9 (2.7-5.5)	0.8 (0.5-1.4)	0.9 (0.6-1.6)	NA	NA	NA	
Limbe	7.2 (6.1-9.0)	1.3 (0.9-2.0)	1.3 (0.9-2.0)	7.9 (5.7-10.5)	1.2 (0.7-1.9)	1.0 (0.6-1.8)	NA	NA	NA	
PoEs										
Mwanza	NA	NA	NA	NA	NA	NA	3.4 (2.4-4.7)	Reference	Reference	
Songwe	NA	NA	NA	NA	NA	NA	3.4 (2.2-4.9)	0.9 (0.5-1.5)	1.1 (0.5-2.4)	

238 * Variables for adjustment: sex, age, education, time since last positive SARS-CoV-2 test, contact with a positive SARS-CoV-2 case.

239 † The first age category for travelers is 5-14

240 ‡ Fully vaccinated=2 doses of COVID-19 AstraZeneca or Pfizer vaccine or 1 dose of COVID-19 Johnson & Johnson; Partially=1 dose

241 of COVID-19 AstraZeneca or Pfizer vaccine; Unvaccinated = no vaccine dose

242 § Weakened immune system=HIV status (Yes= HIV positive, No= HIV negative)

243 Discussion

244 This sentinel surveillance was among the initial steps towards implementing integrated COVID-
245 19 and Influenza surveillance in a resource limited setting (7). The sentinel surveillance offered
246 an opportunity to re-train health workers on the need for continued active tracking of COVID-19
247 cases and routinize surveillance amidst other priority programs and emerging outbreaks. This in
248 turn provided an opportunity for systems strengthening at all levels. The methodology used
249 offered a unique possibility to evaluate the two different surveillance approaches within the same
250 health system as the country prepared for a full integrated surveillance approach (7). Although
251 the influenza component was not fully incorporated during this period, the ability to detect
252 COVID-19 cases in both symptomatic and asymptomatic populations using the integrated
253 COVID-19/Influenza case definition means that, to some extent, integration would be a feasible
254 and potentially efficient approach, particularly in resource limited countries. On the contrary, the
255 routine system alone could easily miss asymptomatic patients particularly in the Malawi settings
256 where the COVID-19 testing targeted those with symptoms. (12)

257 This sentinel surveillance helped bridge some gaps of inadequate SARS-CoV-2 testing, as some
258 routine testing sites in Malawi were not conducting tests at all according to unpublished data
259 from daily COVID-19 updates. The low testing at some routine sites might have been due to the
260 general relaxation of COVID-19 control measures, which is commonly observed during low
261 incidence periods when preventative communications and other measures tend to be minimal
262 (13). The other reason for low testing could be the shifting of attention of surveillance efforts to
263 other emergencies at the time, specifically the national-wide cholera outbreak that begun in
264 March 2022. (5)

265 The difference in sex distribution among participants enrolled from the HFs as compared to the
266 PoEs might reflect some known differences in gender and childbearing roles. Due to their roles
267 in childbearing and primary caregiving for children, women go to health facilities more often
268 than men. On the other hand, men, due to their perceived primary roles as home providers, are
269 often more engaged than females in travelling for businesses (14).

270 The trend showed a relatively higher positivity rate at the beginning of the surveillance period,
271 which may be an overestimation due to the smaller sample size during that early phase." (15).

272 The rest of the epidemiological curve from the COVID-19 sentinel surveillance was comparable
273 to the overall curve inclusive of all other cases tested in the routine surveillance sites (16). This
274 epidemiology curve, which was relatively flat compared to the previous year, aligns with the
275 predictions made by Jiang F and colleagues based on their statistical simulation models. They
276 suggested that this flattening is probably a result of the combined effect of various preventative
277 measures, including immunizations, as control strategies in most countries became more
278 systematic. (17)

279 In this surveillance, the similarity in the trends of positivity rate among symptomatic and
280 asymptomatic population highlight the need for targeting both populations for testing and
281 preventative measures Asymptomatic SARS-CoV-2 cases can be targeted through various
282 strategies, such as testing those who had contact with confirmed cases and incorporating
283 asymptomatic testing into integrated surveillance by deliberately sampling asymptomatic
284 patients on a weekly basis (18).

285 Various factors were evaluated to be associated with SARS-CoV-2 positivity rate in this
286 surveillance. The positive association for students and employees may be explained by their
287 increased risk, as these occupations are more likely to involve physical contact than those who

288 are not employed. Similarly, Mangochi hospital and Mzuzu urban health centre showed a higher
289 likelihood of a SARS-CoV-2 positivity rate as compared to Bwaila urban in Lilongwe city. This
290 could be due to a complex interplay of different socio-economic factors such as level of
291 education and access to health preventative services considering the differences in levels of
292 urbanization in these districts (17,19). These in-country district level differences are relevant for
293 prioritizing resources in resource limited settings. Asymptomatic HF participants who had
294 traveled outside the country within the past 14 days were less likely to test positive to SARS-
295 CoV-2. Travelling history might have lowered their overall risk through mandatory screening
296 procedures and awareness campaigns that were in place in many countries' PoEs (20).

297 This surveillance found that those who were partially vaccinated among the symptomatic group
298 in HF and the travelers who were fully vaccinated were more likely to test positive to SARS-
299 CoV-2 compared to the unvaccinated. This association was not observed in the asymptomatic
300 group in HF for both partially and fully vaccinated categories, and among travelers who were
301 partially vaccinated. These inconsistent findings across the categories need to be interpreted with
302 caution considering some limitations of this surveillance. To start with, COVID-19 vaccination
303 status was self-reported, thus subject to reporting and misclassification biases. Secondly, the
304 smaller numbers of those that were fully/partially vaccinated, can result in less precise estimates
305 of effect sizes. Therefore, given these inconsistent findings across the categories, the complexity
306 of the issue and the limitations of this study, we would need further evaluations to explain the
307 possible reasons for this association. Suffice to say that the evidence of COVID-19 vaccination
308 efficacy and effectiveness is well-documented, particularly for preventing symptomatic disease
309 (21,22). As a recommendation, there is need for intentionally designed surveillances to
310 incorporate some behavioral issues that may impact COVID-19 vaccination effectiveness at

311 population level. Additionally, an important phenomenon that should be kept in check is the so-
312 called “Peltzman Effect”. This refers to a behavioral compensation mechanism whereby
313 individuals would not adhere to precautionary measures due to the perceived protection from
314 vaccine (23). This phenomenon, if at work within a population, would result in increased
315 COVID-19 transmission in the vaccinated population that does not comply to preventative
316 measures.

317 In general, this surveillance had some limitations. The results do not represent the entire
318 population as this was limited to a defined high-risk population that would differ in some
319 epidemiological factors. Additionally, considering the nature of the desired population, the
320 sampling methodology in the health facilities could not be left to systematic sampling, as was in
321 our first protocol design, as that would affect the sample size as was shown during piloting. The
322 use of consecutive sampling for both symptomatic and asymptomatic groups means that
323 selection bias cannot be excluded. Lastly, our questionnaire did not collect data on some other
324 key areas, such as disease severity and COVID-19 vaccination behavioral questions.

325 Conclusion

326 This COVID-19 active sentinel surveillance complemented routine passive surveillance and was
327 instrumental in the low incidence period. The surveillance offered lessons to feed into a full
328 integration approach of COVID-19 and Influenza surveillance in Malawi as per WHO
329 recommendations. The lower observed prevalence of SARS-CoV-2 and the relatively flat trend
330 imply that some preventative measures and systems were in place and working. The ongoing
331 detection of cases in both symptomatic and asymptomatic groups, however, underscores the
332 important need of continuous COVID-19 surveillance in all populations. Moreover, the ongoing

333 detection of infections among travelers, despite instituted COVID-19 travel restrictions, indicates
334 the need for continued surveillance and provides an opportunity to detect novel variants coming
335 into the country. The results also underscore the need for in-depth study of the interaction
336 between COVID-19 vaccinations and behavioral adherence to preventative measures so that
337 sensitization messages can be formulated according to context and evidence.

338 Acknowledgments

339 The authors thank the people of Malawi and the international organizations that contributed to
340 this work.

341 **Disclaimer:** The findings and conclusions in this manuscript are those of the authors and do not
342 necessarily represent the official position of the funding agency.

343 Author Biography

344 Godwin Ulaya (MPH, MBBS) led the COVID-19 Surveillance initiative at I-TECH Malawi and
345 Public Health Institute of Malawi (PHIM). As a Project manager, his role involved mobilizing
346 various Stakeholders in responding to the pandemic. With an interest in epidemiological research
347 and management, he has been involved in various health programs under Ministry of Health,
348 Malawi and in Clinical trials whilst at Johns Hopkins Research Project.

349 References

- 350 1. UNICEF Malawi COVID-19 Situation Report 7 April | UNICEF Malawi [Internet].
351 [cited 2023 Oct 23]. Available from: [https://www.unicef.org/malawi/documents/unicef-](https://www.unicef.org/malawi/documents/unicef-malawi-covid-19-situation-report-7-april)
352 [malawi-covid-19-situation-report-7-april](https://www.unicef.org/malawi/documents/unicef-malawi-covid-19-situation-report-7-april).

- 353 2. Framework for a Public Health Emergency Operations Centre [Internet]. [cited 2023 Jul
354 6]. Available from: [https://www.who.int/publications-detail-redirect/framework-for-a-](https://www.who.int/publications-detail-redirect/framework-for-a-public-health-emergency-operations-centre)
355 [public-health-emergency-operations-centre](https://www.who.int/publications-detail-redirect/framework-for-a-public-health-emergency-operations-centre).
- 356 3. Wadvalla BA. How Africa has tackled covid-19. *BMJ*. 2020 Jul 16;370:m2830.
- 357 4. Tan J, Ge Y, Martinez L, Sun J, Li C, Westbrook A, et al. Transmission roles of
358 symptomatic and asymptomatic COVID-19 cases: a modelling study. *Epidemiol Infect*.
359 2022 Jan;150:e171.
- 360 5. Cholera - Malawi [Internet]. [cited 2023 Jul 6]. Available from:
361 <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON435>.
- 362 6. Polio Outbreak in Malawi | UNICEF Malawi [Internet]. [cited 2024 Jul 21]. Available
363 from: <https://www.unicef.org/malawi/polio-outbreak-malawi>.
- 364 7. End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised
365 interim guidance [Internet]. [cited 2023 Jul 6]. Available from:
366 [https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Integrated_sentinel_surveillance-2022.1)
367 [Integrated_sentinel_surveillance-2022.1](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Integrated_sentinel_surveillance-2022.1)
- 368 8. Theu JA, Kabaghe AN, Bello G, Chitsa-Banda E, Kagoli M, Auld A, et al. SARS-CoV-
369 2 Prevalence in Malawi Based on Data from Survey of Communities and Health
370 Workers in High-Burden Districts, October 2020. *Emerg Infect Dis*. 2022
371 Dec;28(Suppl 1):S76–84.

- 372 9. FAQ: Citing Stata software, documentation, and FAQs | Stata [Internet]. [cited 2024 Jul
373 24]. Available from: [https://www.stata.com/support/faqs/resources/citing-software-
documentation-faqs/](https://www.stata.com/support/faqs/resources/citing-software-
374 documentation-faqs/)
- 375 10. Protections (OHRP) O for HR. 45 CFR 46 [Internet]. 2016 [cited 2023 Oct 31].
376 Available from: [https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-
46/index.html](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-
377 46/index.html)
- 378 11. Pattullo EL. Commentary: Exemption from Review, Not Informed Consent. IRB Ethics
379 Hum Res. 1987;9(5):6–8.
- 380 12. Tempia S, Naja HAE, Barakat A, Abubakar A, Khan W. Integrated surveillance for
381 high-impact respiratory viruses: a necessity for better epidemic and pandemic
382 preparedness. *BMJ Glob Health*. 2022 Jul 1;7(Suppl 4):e009018.
- 383 13. Lin L, Song Y, Wang Q, Pu J, Sun FY, Zhang Y, et al. Public Attitudes and Factors of
384 COVID-19 Testing Hesitancy in the United Kingdom and China: Comparative
385 Infodemiology Study. *JMIR Infodemiology*. 2021 Aug 27;1(1):e26895.
- 386 14. Karmakar M, Lantz PM, Tipirneni R. Association of Social and Demographic Factors
387 With COVID-19 Incidence and Death Rates in the US. *JAMA Netw Open*. 2021 Jan
388 29;4(1):e2036462.
- 389 15. Jones S, Carley S, Harrison M. An introduction to power and sample size estimation.
390 *Emerg Med J EMJ*. 2003 Sep;20(5):453–8.
- 391 16. COVID-19 cases | WHO COVID-19 dashboard. Available from:
392 <https://data.who.int/dashboards/covid19/cases>.

- 393 17. Jiang F, Zhao Z, Shao X. Time series analysis of COVID-19 infection curve: A change-
394 point perspective. *J Econom.* 2023 Jan 1;232(1):1–17.
- 395 18. Schuetz AN, Hemarajata P, Mehta N, Campbell S, Mitchell S, Palavecino E, et al.
396 When Should Asymptomatic Persons Be Tested for COVID-19? *J Clin Microbiol.* 2020
397 Dec 17;59(1):10.1128/jcm.02563-20.
- 398 19. Urbanization in Malawi: Building inclusive & sustainable cities [Internet]. [cited 2023
399 Dec 12]. Available from: <https://unhabitat.org/malawi>.
- 400 20. Public Health (Corona Virus and COVID-19) (Prevention, Containment and
401 Management) (Amendment) (No. 2) Rules, 2021 [Internet]. 2021 [cited 2024 Jul 24].
402 Available from: <https://malawilii.org/akn/mw/act/gn/2021/26/eng@2021-04-23>.
- 403 21. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
404 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med.* 2021 Feb
405 4;384(5):403–16.
- 406 22. Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early
407 effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1
408 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in
409 older adults in England [Internet]. medRxiv; 2021 [cited 2023 Jul 8]. p.
410 2021.03.01.21252652. Available from:
411 <https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1>.
- 412 23. Trogen B, Caplan A. Risk Compensation and COVID-19 Vaccines. *Ann Intern Med.*
413 2021 Jun 15;174(6):858–9.

414

415 **Address for correspondence:** Godwin Ulaya, I-TECH Malawi Plot 13/14 1st floor ARWA


416 House, City Centre, Lilongwe. P O Box 30369, Lilongwe Malawi; **email:**

417 godwin.ulaya@gmail.com




Figure 1: Map showing the seven COVID-19 sentinel sites across Malawi, July – December 2022

HF: health facility, POE: point of entry



medRxiv preprint doi: <https://doi.org/10.1101/2024.12.23.24119583>; this version posted December 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure 1: Flow diagram of participants inclusion, COVID-19 sentinel surveillance, Malawi, July -December 2022



medRxiv preprint doi: <https://doi.org/10.1101/2024.12.23.24319583>; this version posted December 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure 1: Trends of cumulative COVID-19 positivity rate, overall, among symptomatic and asymptomatic, and travelers, COVID-19 sentinel surveillance, Malawi, July-December 2022. Graph shows overall positivity rates, as well as rates among symptomatic and asymptomatic individuals in health facilities (HF) and travelers (lines), along with the number of participants enrolled (bars) over time.

medRxiv preprint doi: <https://doi.org/10.1101/2024.12.23.24319583>; this version posted December 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

